Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives

IF 0.3 Q4 OBSTETRICS & GYNECOLOGY
Muhammad Adil , Ghazanfar Abbas , Mavara Iqbal , Sarmad Rasheed , Shamsa Kanwal
{"title":"Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives","authors":"Muhammad Adil ,&nbsp;Ghazanfar Abbas ,&nbsp;Mavara Iqbal ,&nbsp;Sarmad Rasheed ,&nbsp;Shamsa Kanwal","doi":"10.1016/j.senol.2024.100658","DOIUrl":null,"url":null,"abstract":"<div><div>Angiogenesis exhibits an integral role in cancer development and metastasis, therefore, antiangiogenic therapy forms the basis of several promising treatment strategies for breast cancer. Moreover, DNA damage has long been exploited in cancer chemotherapy and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors constitute a novel group of drugs for the targeted disruption of DNA repair phenomenon attributed to breast cancer. Several antiangiogenic drugs and PARP inhibitors are effectively used as sole agents for the therapeutic management of early breast cancer and breast cancer gene mutation–induced breast cancer, respectively. Whereas, other antiangiogenic agents are employed for the ancillary therapy of metastatic breast cancer in conjunction with chemotherapeutic drugs. Likewise, some PARP inhibitors are recommended as adjuncts to chemotherapy against the triple-negative form of breast cancer. Combinations of PARP inhibitors with immunotherapy have also demonstrated favorable outcomes and offer an efficient treatment strategy for breast cancer. Currently, the combinations of antiangiogenic agents and PARP inhibitors are under investigation for prospective synergistic or additive effects in breast cancer. Despite being suggested for high-risk patients, the prophylactic use of PARP inhibitors has not been supported by means of preclinical or clinical studies. Finally, the identification of patient cohorts, determination of predictive biomarkers, optimization of dosing strategies, validation of long-term safety, and containment of resistance issues, necessitate proper attention for improving the clinical efficacy of potentially useful antiangiogenic agents and PARP inhibitors against breast cancer.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100658"},"PeriodicalIF":0.3000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158224000860","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Angiogenesis exhibits an integral role in cancer development and metastasis, therefore, antiangiogenic therapy forms the basis of several promising treatment strategies for breast cancer. Moreover, DNA damage has long been exploited in cancer chemotherapy and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors constitute a novel group of drugs for the targeted disruption of DNA repair phenomenon attributed to breast cancer. Several antiangiogenic drugs and PARP inhibitors are effectively used as sole agents for the therapeutic management of early breast cancer and breast cancer gene mutation–induced breast cancer, respectively. Whereas, other antiangiogenic agents are employed for the ancillary therapy of metastatic breast cancer in conjunction with chemotherapeutic drugs. Likewise, some PARP inhibitors are recommended as adjuncts to chemotherapy against the triple-negative form of breast cancer. Combinations of PARP inhibitors with immunotherapy have also demonstrated favorable outcomes and offer an efficient treatment strategy for breast cancer. Currently, the combinations of antiangiogenic agents and PARP inhibitors are under investigation for prospective synergistic or additive effects in breast cancer. Despite being suggested for high-risk patients, the prophylactic use of PARP inhibitors has not been supported by means of preclinical or clinical studies. Finally, the identification of patient cohorts, determination of predictive biomarkers, optimization of dosing strategies, validation of long-term safety, and containment of resistance issues, necessitate proper attention for improving the clinical efficacy of potentially useful antiangiogenic agents and PARP inhibitors against breast cancer.
抗血管生成药物和多腺苷二磷酸核糖聚合酶(PARP)抑制剂在乳腺癌中的治疗意义:现状和未来展望
血管生成在癌症的发展和转移中发挥着不可或缺的作用,因此,抗血管生成治疗是几种有前景的乳腺癌治疗策略的基础。此外,DNA损伤早已被用于癌症化疗,多腺苷二磷酸核糖聚合酶(PARP)抑制剂构成了一组新的药物,用于靶向破坏乳腺癌的DNA修复现象。几种抗血管生成药物和PARP抑制剂分别被有效地用作早期乳腺癌和乳腺癌基因突变引起的乳腺癌的治疗管理的唯一药物。然而,其他抗血管生成药物与化疗药物一起用于转移性乳腺癌的辅助治疗。同样,一些PARP抑制剂也被推荐作为治疗三阴性乳腺癌的辅助化疗。PARP抑制剂联合免疫疗法也显示出良好的结果,并为乳腺癌提供了一种有效的治疗策略。目前,抗血管生成药物和PARP抑制剂的组合正在研究在乳腺癌中的预期协同或相加效应。尽管建议高危患者预防性使用PARP抑制剂,但尚未得到临床前或临床研究的支持。最后,确定患者队列,确定预测性生物标志物,优化给药策略,验证长期安全性,以及遏制耐药性问题,需要适当关注提高潜在有用的抗血管生成药物和PARP抑制剂对乳腺癌的临床疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista de Senologia y Patologia Mamaria
Revista de Senologia y Patologia Mamaria Medicine-Obstetrics and Gynecology
CiteScore
0.30
自引率
0.00%
发文量
74
审稿时长
63 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信